Efficacy of a Novel Sigma-1 Receptor Antagonist for Oxaliplatin-Induced Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Clinical Trial.
Bruna J, Videla S, Argyriou AA, Velasco R, Villoria J, Santos C, Nadal C, Cavaletti G, Alberti P, Briani C, Kalofonos HP, Cortinovis D, Sust M, Vaqué A, Klein T, Plata-Salamán C.
Bruna J, et al. Among authors: sust m.
Neurotherapeutics. 2018 Jan;15(1):178-189. doi: 10.1007/s13311-017-0572-5.
Neurotherapeutics. 2018.
PMID: 28924870
Free PMC article.
Clinical Trial.